What is Chardan Capital’s Estimate for LXEO FY2025 Earnings?

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Chardan Capital reduced their FY2025 earnings per share estimates for Lexeo Therapeutics in a research note issued on Tuesday, March 25th. Chardan Capital analyst G. Livshits now expects that the company will post earnings of ($3.10) per share for the year, down from their prior forecast of ($2.30). Chardan Capital currently has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share.

Other analysts have also issued research reports about the stock. Royal Bank of Canada dropped their price target on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research report on Tuesday. HC Wainwright restated a “buy” rating and issued a $23.00 price target on shares of Lexeo Therapeutics in a research note on Wednesday. Finally, Leerink Partners decreased their price objective on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a report on Monday, March 24th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Lexeo Therapeutics has an average rating of “Buy” and an average target price of $22.80.

Lexeo Therapeutics Trading Down 0.2 %

Shares of NASDAQ:LXEO opened at $4.10 on Friday. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. Lexeo Therapeutics has a 12-month low of $2.32 and a 12-month high of $19.50. The business has a 50 day moving average of $4.05 and a two-hundred day moving average of $6.58. The company has a market capitalization of $135.57 million, a PE ratio of -1.30 and a beta of 3.85.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.09.

Institutional Investors Weigh In On Lexeo Therapeutics

Several large investors have recently modified their holdings of the company. Allostery Investments LP purchased a new position in Lexeo Therapeutics during the 4th quarter worth $33,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Lexeo Therapeutics in the 4th quarter valued at approximately $46,000. BNP Paribas Financial Markets increased its holdings in shares of Lexeo Therapeutics by 184.2% in the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock valued at $50,000 after purchasing an additional 3,591 shares during the period. Price T Rowe Associates Inc. MD purchased a new stake in shares of Lexeo Therapeutics during the fourth quarter worth approximately $69,000. Finally, SG Americas Securities LLC purchased a new position in Lexeo Therapeutics in the 4th quarter valued at $72,000. 60.67% of the stock is owned by institutional investors and hedge funds.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.